BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:EPFL BioE Talks SERIES  "Towards the Development of Orally Availab
 le Cyclic Peptides"
DTSTART:20210301T163000
DTEND:20210301T170000
DTSTAMP:20260916T055414Z
UID:e60c84133d946a5efec2f55d8cc341b39c6ad38617bcfe6a0ca08490
CATEGORIES:Conferences - Seminars
DESCRIPTION:Prof. Christian Heinis\, Institute of Chemical Sciences and En
 gineering\, EPFL\, Lausanne (CH)\nWEEKLY EPFL BIOE TALKS SERIES\n\n(note t
 hat this talk is number two of a double-feature seminar - see details of t
 he first talk here)\n\nAbstract:\nMy laboratory is engaged in the discover
 y and development of cyclic peptides for therapeutic application. We gener
 ate the cyclic peptides by screening large combinatorial libraries against
  disease targets using phage display and microplate-based screens. The lib
 raries are synthesized by efficient macrocyclization reactions applied to 
 either phage-displayed peptides or synthetic peptides produced on solid ph
 ase. We have demonstrated the pharmacological activity of several of the c
 yclic peptides in vivo.\n\nIn recent years\, we have started to address th
 e long-standing goal of developing orally available peptides. In my talk\,
  I will introduce the bicyclic peptide phage display technology [1] and th
 en present a recently developed new peptide format that we termed "double-
 bridged peptides" [2]\, that allows for generating proteolytically stable 
 peptides. I will show how we generated peptides that remain fully intact i
 n all regions of the gastrointestinal tract upon oral administration to mi
 ce [3]. In a second part of my talk\, I will present first results of a ne
 w approach for the high-throughput screening of sub-kDa peptide macrocycle
 s that we have developed with the aim of generating orally available or ev
 en cell permeable peptides [4].\n\nReferences:\n[1] C. Heinis\, et al.\, N
 ature Chemical Biology. 2009\, 5 (7)\, 502.\n[2] S. Kale\, et al.\, Nature
  Chemistry. 2018\, 10 (7)\, 715.\n[3] X.-K. Kong\, et al.\, Nature Biomedi
 cal Engineering. 2020\n[4] S. Kale\, et al.\, Science Advances. 2019\, 5 (
 8).\n\nBio:\nChristian Heinis studied chemistry/biochemistry at the ETH Zu
 rich. After a PhD in the research group of Prof. Dr. Dario Neri at ETH Zur
 ich\, he did two post-docs\, the first one with Prof. Dr. Kai Johnsson at 
 the EPFL in Lausanne and the second one with Sir Gregory Winter at the LMB
 -MRC in Cambridge\, UK. In 2008 he started as Assistant Professor at EPFL 
 (supported with an SNSF professorship) and was promoted in 2015 to Associa
 te Professor. Christian Heinis is co-founder of the company Bicycle Therap
 eutics. He is co-director of the Swiss research network NCCR Chemical Biol
 ogy.\n\n\nZoom link (with registration) for attending remotely: https://go
 .epfl.ch/EPFLBioETalks\n\n\nIMPORTANT NOTICE: due to restrictions resultin
 g from the ongoing Covid-19 pandemic\, this seminar can be followed via Zo
 om web-streaming only\, (following prior one-time registration through the
  link above).
LOCATION:via Zoom web-streaming only\, due to Covid-19 pandemic https://go
 .epfl.ch/EPFLBioETalks https://go.epfl.ch/EPFLBioETalks
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR